Article
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
Advances in therapy - 1 Jul 2015
McPhee Fiona, Suzuki Yoshiyuki, Toyota Joji, Karino Yoshiyasu, Chayama Kasuaki, Kawakami Yoshiiku, Yu Min Lung, Ahn Sang Hoon, Ishikawa Hiroki, Bhore Rafia, Zhou Nannan, Hernandez Dennis, Mendez Patricia, Kumada Hiromitsu
Abstract excerpt
INTRODUCTION: Oral daclatasvir (DCV; pangenotypic NS5A inhibitor) plus asunaprevir (ASV; NS3 protease inhibitor) is approved in Japan and Korea for treatment of chronic hepatitis C virus (HCV) genotype 1. Response to DCV + ASV is affected by DCV resistance-associated polymorphisms (RAPs) in HCV NS5A. The prevalence and influence of these RAPs on 12-week sustained virologic response (SVR12) to DCV + ASV was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.